Sarepta Therapeutics, Inc.
SRPT· Nasdaq
SRPTSarepta Therapeutics, Inc.
Filed May 1, 2024 · 10-Q · 31 days after period end · 0000950170-24-051234
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $359.48M | $231.50M | $188.83M | $124.93M |
| Net Income | $36.12M | -$516.76M | -$105.03M | -$167.25M |
| EPS Diluted | $0.37 | -$5.86 | -$1.20 | -$2.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 1, 2024 · 31 d after period end
